HER2/HER3 heterodimers in prostate cancer: Whither HER1/EGFR?

被引：21

作者：

Freeman, MR ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Childrens Hosp Boston, Urol Dis Res Ctr,Enders Res Labs, Boston, MA 02115 USA

来源：

CANCER CELL | 2004年 / 6卷 / 05期

关键词：

D O I：

10.1016/j.ccr.2004.10.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In this issue of Cancer Cell, Mellinghoff et al. (2004) demonstrate that a small molecule inhibitor of the EGF receptor (EGFR) and the HER2/ErbB2/c-Neu kinase blocks signaling to the androgen receptor by a mechanism that involves HER2/HER3 heterodimerization. Surprisingly, the EGFR is peripheral to this signaling mechanism. These results have implications for the design of targeted therapy for hormone-refractory prostate cancer.

引用

页码：427 / 428

页数：2

共 50 条

[41] Quantification of HER1, HER2 and HER3 by time-resolved Forster resonance energy transfer in FFPE triple-negative breast cancer samples
Ho-Pun-Cheung, Alexandre
Bazin, Herve
Boissiere-Michot, Florence
Mollevi, Caroline
Simony-Lafontaine, Joelle
Landas, Emeline
Bleuse, Jean-Pierre
Chardes, Thierry
Prost, Jean-Francois
Pelegrin, Andre
Jacot, William
Mathis, Gerard
Lopez-Crapez, Evelyne
BRITISH JOURNAL OF CANCER, 2020, 122 (03) : 397 - 404
[42] Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors
Steffensen, Karina Dahl
Waldstrom, Marianne
Andersen, Rikke Fredslund
Olsen, Dorte Aalund
Jeppesen, Ulla
Knudsen, Hans Jorgen
Brandslund, Ivan
Jakobsen, Anders
INTERNATIONAL JOURNAL OF ONCOLOGY, 2008, 33 (01) : 195 - 204
[43] In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer
Melanie Spears
Karen J. Taylor
Alison F. Munro
Carrie A. Cunningham
Elizabeth A. Mallon
Chris J. Twelves
David A. Cameron
Jeremy Thomas
John M. S. Bartlett
Breast Cancer Research and Treatment, 2012, 132 : 463 - 470
[44] Triple negative breast cancer is vulnerable to Pan-HER, an antibody mixture simultaneously targeting EGFR, HER2 and HER3
Choi, D. S.
Qian, W.
Davila-Gonzalez, D.
Ensor, J. E.
Lantto, J.
Kragh, M.
Horak, I. D.
Chang, J. C.
CANCER RESEARCH, 2016, 76
[45] Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer
Xiu Li Zhang
Yun Sheng Yang
Dong Ping Xu
Jian Hui Qu
Ming Zhou Guo
Yan Gong
Jin Huang
World Journal of Surgery, 2009, 33 : 2112 - 2118
[46] Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
Reid, Alison
Vidal, Laura
Shaw, Heather
de Bono, Johann
EUROPEAN JOURNAL OF CANCER, 2007, 43 (03) : 481 - 489
[47] EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer
Fichter, Christiane Daniela
Timme, Sylvia
Braun, Julia Alexandra
Gudernatsch, Verena
Schoepflin, Anja
Bogatyreva, Lioudmilla
Geddert, Helene
Faller, Gerhard
Klimstra, David
Tang, Laura
Hauschke, Dieter
Werner, Martin
Lassmann, Silke
INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (07) : 1517 - 1530
[48] Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer
Zhang, Xiu Li
Yang, Yun Sheng
Xu, Dong Ping
Qu, Jian Hui
Guo, Ming Zhou
Gong, Yan
Huang, Jin
WORLD JOURNAL OF SURGERY, 2009, 33 (10) : 2112 - 2118
[49] Co-occurring gain-of-function mutations in HER2 and HER3 cooperate to enhance HER2/HER3 binding, HER-dependent signaling, and breast cancer growth
Hanker, A. B.
Koch, J. P.
Ye, D.
Sliwoski, G.
Sheehan, J.
Kinch, L. N.
Brewer, M. Red
He, J.
Miller, V. A.
Lalani, A. S.
Cutler, R. E., Jr.
Croessmann, S.
Zabransky, D. J.
Meiler, J.
Arteaga, C. L.
CANCER RESEARCH, 2019, 79 (04)
[50] A novel pan-HER ligand trap based on human EGFR (HER1) and HER3 inhibits tumor growth and metastasis in models of human cancer
Huang, Z.
Shepard, H. M.
Maneval, D.
Jin, P.
Beryt, M.
Zhang, J.
Brdlik, C.
Cousens, L.
Jorgensen, B.
Bai, X.
EJC SUPPLEMENTS, 2008, 6 (12): : 101 - 101

← 1 2 3 4 5 →